{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:10:01Z","timestamp":1786122601849,"version":"build-2736575974"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-74790-7","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T17:26:35Z","timestamp":1782321995000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multimodal blood based proteomic profiling reveals insights into mechanisms of immunotherapy resistance"],"prefix":"10.1038","volume":"17","author":[{"given":"Samuel J.","family":"Wright","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izabella","family":"Zamora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1336-7883","authenticated-orcid":false,"given":"Milan","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepika","family":"Yeramosu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijana","family":"Rucevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0022-0287","authenticated-orcid":false,"given":"Moshe","family":"Sade-Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8390-6072","authenticated-orcid":false,"given":"Thomas J.","family":"LaSalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8656-8216","authenticated-orcid":false,"given":"Emily M.","family":"Blaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baolin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Blum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngan","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamey","family":"Guess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrita","family":"Kar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2158-6915","authenticated-orcid":false,"given":"Alexis M.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliot","family":"Woods","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3664-2094","authenticated-orcid":false,"given":"William","family":"Michaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3861-3164","authenticated-orcid":false,"given":"Aleigha R.","family":"Lawless","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Sharova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyulnara","family":"Kasumova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Chun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7461-0408","authenticated-orcid":false,"given":"Alexandra-Chlo\u00e9","family":"Villani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4725-2937","authenticated-orcid":false,"given":"Ryan J.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6110-2148","authenticated-orcid":false,"given":"Russell W.","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel J.","family":"Klempner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5344-6645","authenticated-orcid":false,"given":"Ryan J.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3402-0478","authenticated-orcid":false,"given":"Keith T.","family":"Flaherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2349-2656","authenticated-orcid":false,"given":"Nir","family":"Hacohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0313-2848","authenticated-orcid":false,"given":"Arnav","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7522-6173","authenticated-orcid":false,"given":"Genevieve M.","family":"Boland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"74790_CR1","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. New Engl. J. Med. 372, 2521\u20132532 (2015).","journal-title":"New Engl. J. Med."},{"key":"74790_CR2","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok, J. D. et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. New Engl. J. Med. 377, 1345\u20131356 (2017).","journal-title":"New Engl. J. Med."},{"key":"74790_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. New Engl. J. Med. 373, 23\u201334 (2015).","journal-title":"New Engl. J. Med."},{"key":"74790_CR4","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1038\/s41591-019-0654-5","volume":"25","author":"D Liu","year":"2019","unstructured":"Liu, D. et al. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat. Med. 25, 1916\u20131927 (2019).","journal-title":"Nat. Med."},{"key":"74790_CR5","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/s41591-020-0839-y","volume":"26","author":"DA Braun","year":"2020","unstructured":"Braun, D. A. et al. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat. Med. 26, 909\u2013918 (2020).","journal-title":"Nat. Med."},{"key":"74790_CR6","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.cell.2020.09.001","volume":"183","author":"BY Nabet","year":"2020","unstructured":"Nabet, B. Y. et al. Noninvasive early identification of therapeutic benefit from immune checkpoint inhibition. Cell 183, 363\u2013376 (2020).","journal-title":"Cell"},{"key":"74790_CR7","doi-asserted-by":"publisher","first-page":"5482","DOI":"10.1016\/j.cell.2021.09.014","volume":"184","author":"BA Luca","year":"2021","unstructured":"Luca, B. A. et al. Atlas of clinically distinct cell states and ecosystems across human solid tumors. Cell 184, 5482\u20135496 (2021).","journal-title":"Cell"},{"key":"74790_CR8","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/s41588-020-00739-1","volume":"52","author":"JR Conway","year":"2020","unstructured":"Conway, J. R. et al. Integrated molecular drivers coordinate biological and clinical states in melanoma. Nat. Genet. 52, 1373\u20131383 (2020).","journal-title":"Nat. Genet."},{"key":"74790_CR9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","volume":"165","author":"W Hugo","year":"2016","unstructured":"Hugo, W. et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165, 35\u201344 (2016).","journal-title":"Cell"},{"key":"74790_CR10","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1158\/2159-8290.CD-21-0219","volume":"11","author":"M Kwon","year":"2021","unstructured":"Kwon, M. et al. Determinants of response and intrinsic resistance to PD-1 blockade in microsatellite instability\u2013high gastric cancer. Cancer Discov. 11, 2168\u20132185 (2021).","journal-title":"Cancer Discov."},{"key":"74790_CR11","doi-asserted-by":"publisher","first-page":"e003521","DOI":"10.1136\/jitc-2021-003521","volume":"9","author":"R Reschke","year":"2021","unstructured":"Reschke, R. et al. Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma. J. Immunother. Cancer 9, e003521 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"74790_CR12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41576-018-0071-5","volume":"20","author":"E Heitzer","year":"2019","unstructured":"Heitzer, E., Haque, I. S., Roberts, C. E. S. & Speicher, M. R. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat. Rev. Genet. 20, 71\u201388 (2019).","journal-title":"Nat. Rev. Genet."},{"key":"74790_CR13","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1126\/science.aar3247","volume":"359","author":"JD Cohen","year":"2018","unstructured":"Cohen, J. D. et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 359, 926\u2013930 (2018).","journal-title":"Science"},{"key":"74790_CR14","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1056\/NEJMra1706174","volume":"379","author":"RB Corcoran","year":"2018","unstructured":"Corcoran, R. B. & Chabner, B. A. Application of cell-free DNA analysis to cancer treatment. New Engl. J. Med. 379, 1754\u20131765 (2018).","journal-title":"New Engl. J. Med."},{"key":"74790_CR15","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.ccell.2020.03.012","volume":"37","author":"E Kilgour","year":"2020","unstructured":"Kilgour, E., Rothwell, D. G., Brady, G. & Dive, C. Liquid biopsy-based biomarkers of treatment response and resistance. Cancer Cell 37, 485\u2013495 (2020).","journal-title":"Cancer Cell"},{"key":"74790_CR16","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/s41591-024-03398-5","volume":"31","author":"S-K Yoo","year":"2025","unstructured":"Yoo, S.-K. et al. Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data. Nat. Med. 31, 869\u2013880 (2025).","journal-title":"Nat. Med."},{"key":"74790_CR17","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41591-019-0734-6","volume":"26","author":"BP Fairfax","year":"2020","unstructured":"Fairfax, B. P. et al. Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma. Nat. Med. 26, 193\u2013199 (2020).","journal-title":"Nat. Med."},{"key":"74790_CR18","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/nature22079","volume":"545","author":"AC Huang","year":"2017","unstructured":"Huang, A. C. et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545, 60\u201365 (2017).","journal-title":"Nature"},{"key":"74790_CR19","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41586-020-2056-8","volume":"579","author":"TD Wu","year":"2020","unstructured":"Wu, T. D. et al. Peripheral T cell expansion predicts tumour infiltration and clinical response. Nature 579, 274\u2013278 (2020).","journal-title":"Nature"},{"key":"74790_CR20","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/nm.4466","volume":"24","author":"C Krieg","year":"2018","unstructured":"Krieg, C. et al. High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. Nat. Med. 24, 144\u2013153 (2018).","journal-title":"Nat. Med."},{"key":"74790_CR21","doi-asserted-by":"publisher","first-page":"e000204","DOI":"10.1136\/jitc-2019-000204","volume":"8","author":"H Baba\u010di\u0107","year":"2020","unstructured":"Baba\u010di\u0107, H., Lehti\u00f6, J., Pico de Coa\u00f1a, Y., Pernemalm, M. & Eriksson, H. In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma. J. Immunother. Cancer 8, e000204 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"74790_CR22","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/s41591-020-0856-x","volume":"26","author":"KA Schalper","year":"2020","unstructured":"Schalper, K. A. et al. Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors. Nat. Med. 26, 688\u2013692 (2020).","journal-title":"Nat. Med."},{"key":"74790_CR23","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41591-020-0860-1","volume":"26","author":"KC Yuen","year":"2020","unstructured":"Yuen, K. C. et al. High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade. Nat. Med. 26, 693\u2013698 (2020).","journal-title":"Nat. Med."},{"key":"74790_CR24","doi-asserted-by":"crossref","unstructured":"Simonelli, M. et al. 121MO anti-IL-8 (BMS-986253) in combination with nivolumab (NIVO) plus ipilimumab (IPI) in patients (pts) with advanced melanoma: final analysis from the randomized part 2 of the phase I\/II CA027-002 study. Immuno Oncol. Technol. 24 (2024).","DOI":"10.1016\/j.iotech.2024.100750"},{"key":"74790_CR25","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3389\/fmed.2018.00351","volume":"5","author":"JA Bridge","year":"2018","unstructured":"Bridge, J. A., Lee, J. C., Daud, A., Wells, J. W. & Bluestone, J. A. Cytokines, chemokines, and other biomarkers of response for checkpoint inhibitor therapy in skin cancer. Front. Med. 5, 351 (2018).","journal-title":"Front. Med."},{"key":"74790_CR26","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1158\/2159-8290.CD-22-0603","volume":"12","author":"F Newell","year":"2022","unstructured":"Newell, F. et al. Comparative genomics provides etiologic and biological insight into melanoma subtypes. Cancer Discov. 12, 2856\u20132879 (2022).","journal-title":"Cancer Discov."},{"key":"74790_CR27","doi-asserted-by":"publisher","first-page":"11553","DOI":"10.1007\/s13277-016-5098-7","volume":"37","author":"N Kumari","year":"2016","unstructured":"Kumari, N., Dwarakanath, B. S., Das, A. & Bhatt, A. N. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumor Biol. 37, 11553\u201311572 (2016).","journal-title":"Tumor Biol."},{"key":"74790_CR28","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/s41591-020-0873-9","volume":"26","author":"Z Bakouny","year":"2020","unstructured":"Bakouny, Z. & Choueiri, T. K. IL-8 and cancer prognosis on immunotherapy. Nat. Med. 26, 650\u2013651 (2020).","journal-title":"Nat. Med."},{"key":"74790_CR29","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.1200\/JCO.21.02511","volume":"40","author":"IM Chen","year":"2022","unstructured":"Chen, I. M. et al. Randomized phase II study of nivolumab with or without ipilimumab combined with stereotactic body radiotherapy for refractory metastatic pancreatic cancer (CheckPAC). J. Clin. Oncol. 40, 3180\u20133189 (2022).","journal-title":"J. Clin. Oncol."},{"key":"74790_CR30","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1038\/s41586-024-08305-z","volume":"637","author":"I Melero","year":"2025","unstructured":"Melero, I. et al. Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours. Nature 637, 1218\u20131227 (2025).","journal-title":"Nature"},{"key":"74790_CR31","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ctrv.2017.11.007","volume":"63","author":"R Tokunaga","year":"2018","unstructured":"Tokunaga, R. et al. CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation\u2014a target for novel cancer therapy. Cancer Treat. Rev. 63, 40\u201347 (2018).","journal-title":"Cancer Treat. Rev."},{"key":"74790_CR32","doi-asserted-by":"crossref","unstructured":"Chia, T.-Y. et al. The CXCL16-CXCR6 axis in glioblastoma modulates T-cell activity in a spatiotemporal context. Front. Immunol. 14, 1331287 (2024).","DOI":"10.3389\/fimmu.2023.1331287"},{"key":"74790_CR33","doi-asserted-by":"crossref","unstructured":"Tooley, K. et al. Pan-cancer mapping of single CD8+ T cell profiles reveals a TCF1:CXCR6 axis regulating CD28 co-stimulation and anti-tumor immunity. Cell Rep. Med. 5, 101640 (2024).","DOI":"10.1016\/j.xcrm.2024.101640"},{"key":"74790_CR34","doi-asserted-by":"publisher","first-page":"152391","DOI":"10.1016\/j.imbio.2023.152391","volume":"228","author":"J Lao","year":"2023","unstructured":"Lao, J. et al. Peripheral changes in T cells predict efficacy of anti-PD-1 immunotherapy in non-small cell lung cancer. Immunobiology 228, 152391 (2023).","journal-title":"Immunobiology"},{"key":"74790_CR35","doi-asserted-by":"crossref","unstructured":"Hou, J., Yang, X., Xie, S., Zhu, B. & Zha, H. Circulating T cells: a promising biomarker of anti-PD-(L)1 therapy. Front. Immunol. 15, 1371559 (2024).","DOI":"10.3389\/fimmu.2024.1371559"},{"key":"74790_CR36","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.medj.2022.12.007","volume":"4","author":"NG Nu\u00f1ez","year":"2023","unstructured":"Nu\u00f1ez, N. G. et al. Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors. Med 4, 113\u2013129 (2023).","journal-title":"Med"},{"key":"74790_CR37","doi-asserted-by":"publisher","first-page":"690201","DOI":"10.3389\/fimmu.2021.690201","volume":"12","author":"L Ardighieri","year":"2021","unstructured":"Ardighieri, L. et al. Infiltration by CXCL10 secreting macrophages is associated with antitumor immunity and response to therapy in ovarian cancer subtypes. Front. Immunol. 12, 690201 (2021).","journal-title":"Front. Immunol."},{"key":"74790_CR38","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/s43018-022-00433-7","volume":"3","author":"B Liu","year":"2022","unstructured":"Liu, B., Zhang, Y., Wang, D., Hu, X. & Zhang, Z. Single-cell meta-analyses reveal responses of tumor-reactive CXCL13+ T cells to immune-checkpoint blockade. Nat. Cancer 3, 1123\u20131136 (2022).","journal-title":"Nat. Cancer"},{"key":"74790_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29366-6","volume":"13","author":"J Qi","year":"2022","unstructured":"Qi, J. et al. Single-cell and spatial analysis reveal interaction of FAP+ fibroblasts and SPP1+ macrophages in colorectal cancer. Nat. Commun. 13, 1742 (2022).","journal-title":"Nat. Commun."},{"key":"74790_CR40","doi-asserted-by":"publisher","first-page":"6173","DOI":"10.3390\/cancers13246173","volume":"13","author":"U \u00c7ak\u0131r","year":"2021","unstructured":"\u00c7ak\u0131r, U. et al. Mesenchymal-stromal cell-like melanoma-associated fibroblasts increase IL-10 production by macrophages in a cyclooxygenase\/indoleamine 2,3-dioxygenase-dependent manner. Cancers 13, 6173 (2021).","journal-title":"Cancers"},{"key":"74790_CR41","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1038\/s41596-020-0292-x","volume":"15","author":"M Efremova","year":"2020","unstructured":"Efremova, M., Vento-Tormo, M., Teichmann, S. A. & Vento-Tormo, R. CellPhoneDB: inferring cell\u2013cell communication from combined expression of multi-subunit ligand\u2013receptor complexes. Nat. Protoc. 15, 1484\u20131506 (2020).","journal-title":"Nat. Protoc."},{"key":"74790_CR42","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1080\/19336918.2015.1008332","volume":"9","author":"T Yoshida","year":"2015","unstructured":"Yoshida, T., Akatsuka, T. & Imanaka-Yoshida, K. Tenascin-C and integrins in cancer. Cell Adhes. Migr. 9, 96\u2013104 (2015).","journal-title":"Cell Adhes. Migr."},{"key":"74790_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0769-1","volume":"17","author":"G Wu","year":"2018","unstructured":"Wu, G. et al. Targeting Gas6\/TAM in cancer cells and tumor microenvironment. Mol. Cancer 17, 20 (2018).","journal-title":"Mol. Cancer"},{"key":"74790_CR44","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1002\/cam4.871","volume":"5","author":"T Shanmugalingam","year":"2016","unstructured":"Shanmugalingam, T., Bosco, C., Ridley, A. J. & Van Hemelrijck, M. Is there a role for IGF-1 in the development of second primary cancers? Cancer Med. 5, 3353\u20133367 (2016).","journal-title":"Cancer Med."},{"key":"74790_CR45","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3390\/biomedicines11010229","volume":"11","author":"A Belfiore","year":"2023","unstructured":"Belfiore, A. et al. IGF2: a role in metastasis and tumor evasion from immune surveillance? Biomedicines 11, 229 (2023).","journal-title":"Biomedicines"},{"key":"74790_CR46","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1002\/cam4.2113","volume":"8","author":"Q Song","year":"2019","unstructured":"Song, Q. et al. Dissecting intratumoral myeloid cell plasticity by single cell RNA-seq. Cancer Med. 8, 3072\u20133085 (2019).","journal-title":"Cancer Med."},{"key":"74790_CR47","doi-asserted-by":"publisher","first-page":"e13116","DOI":"10.1111\/cpr.13116","volume":"54","author":"X Yang","year":"2021","unstructured":"Yang, X. et al. Single-cell profiling reveals distinct immune phenotypes that contribute to ischaemia-reperfusion injury after steatotic liver transplantation. Cell Prolif. 54, e13116 (2021).","journal-title":"Cell Prolif."},{"key":"74790_CR48","doi-asserted-by":"crossref","unstructured":"Love, N. R. et al. Melanoma progression and prognostic models drawn from single-cell, spatial maps of benign and malignant tumors. Sci. Adv. 10, eadm8206 (2024).","DOI":"10.1126\/sciadv.adm8206"},{"key":"74790_CR49","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/ng.2653","volume":"45","author":"J Lonsdale","year":"2013","unstructured":"Lonsdale, J. et al. The Genotype-Tissue Expression (GTEx) Project. Nat. Genet. 45, 580\u2013585 (2013).","journal-title":"Nat. Genet."},{"key":"74790_CR50","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3892\/etm.2022.11577","volume":"24","author":"Q Zhou","year":"2022","unstructured":"Zhou, Q. et al. Macrophages in melanoma: a double\u2011edged sword and targeted therapy strategies (review). Exp. Ther. Med. 24, 640 (2022).","journal-title":"Exp. Ther. Med."},{"key":"74790_CR51","first-page":"49","volume":"11","author":"BB Rogers","year":"2020","unstructured":"Rogers, B. B., Cuddahy, T. & Zawislak, C. Management of acute pancreatitis associated with checkpoint inhibitors. J. Adv. Pract. Oncol. 11, 49 (2020).","journal-title":"J. Adv. Pract. Oncol."},{"key":"74790_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43485-8","volume":"14","author":"A M\u00e4larstig","year":"2023","unstructured":"M\u00e4larstig, A. et al. Evaluation of circulating plasma proteins in breast cancer using Mendelian randomisation. Nat. Commun. 14, 7680 (2023).","journal-title":"Nat. Commun."},{"key":"74790_CR53","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/cyto.a.23904","volume":"97","author":"S Van Gassen","year":"2020","unstructured":"Van Gassen, S., Gaudilliere, B., Angst, M. S., Saeys, Y. & Aghaeepour, N. CytoNorm: a normalization algorithm for cytometry data. Cytometry A 97, 268\u2013278 (2020).","journal-title":"Cytometry A"},{"key":"74790_CR54","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1126\/science.ade2292","volume":"381","author":"R Bill","year":"2023","unstructured":"Bill, R. et al. CXCL9:SPP1 macrophage polarity identifies a network of cellular programs that control human cancers. Science 381, 515\u2013524 (2023).","journal-title":"Science"},{"key":"74790_CR55","doi-asserted-by":"publisher","unstructured":"Fang, J., Salinas, I., Vicente, S. S., Zielinski, C. & Sade-Feldman, M. Dissociation of human and mouse tumor tissue samples for single-cell RNA sequencing. J. Vis. Exp. e66766, https:\/\/doi.org\/10.3791\/66766(2024).","DOI":"10.3791\/66766"},{"key":"74790_CR56","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","volume":"16","author":"I Korsunsky","year":"2019","unstructured":"Korsunsky, I. et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1289\u20131296 (2019).","journal-title":"Nat. Methods"},{"key":"74790_CR57","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41592-022-01728-4","volume":"20","author":"Z Cang","year":"2023","unstructured":"Cang, Z. et al. Screening cell\u2013cell communication in spatial transcriptomics via collective optimal transport. Nat. Methods 20, 218\u2013228 (2023).","journal-title":"Nat. Methods"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74790-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74790-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74790-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T11:03:47Z","timestamp":1786100627000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-74790-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["74790"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-74790-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"assertion":[{"value":"17 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.C.V. has a financial interest in 10\u00d7 Genomics. 10\u00d7 Genomics designs and manufactures gene sequencing technology for use in research, and such technology is being used in this research; these interests were reviewed by the Massachusetts General Hospital and Mass General Brigham in accordance with their institutional policies. R.W.J. is a member of the advisory board for and has a financial interest in Xsphera Biosciences Inc., a company focused on using ex vivo profiling technology to deliver functional, precision immune-oncology solutions for patients, providers, and drug development companies. R.W.J. has received honoraria from Incyte (invited speaker), G1 Therapeutics (advisory board), and Bioxcel Therapeutics (invited speaker). R.W.J. has an ownership interest in U.S. patents US20200399573A9 and US20210363595A1. R.W.J.\u2019s interests were reviewed and are managed by Massachusetts General Hospital and Mass General Brigham in accordance with their conflict-of-interest policies. R.J.S. serves as a consultant\/advisory board member for Marengo Therapeutics, Merck, Novartis, Pfizer, and Replimune, and has received research funding from Merck. N.H. holds equity in and advises Danger Bio\/Related Sciences, is on the scientific advisory board of Repertoire Immune Medicines and CytoReason, owns equity and has licensed patents to BioNtech, and receives research funding from Bristol Myers Squibb, Moderna, JJDC, Takeda, and Calico Life Sciences. A.M. has served a consultant, advisory or board director role for Plexium, SyntheX, Monimoi, Juri Biosciences, CxT Discovery, Third Rock Ventures, Asher Biotherapeutics, Abata Therapeutics, Clasp Therapeutics, Flare Therapeutics, venBio Partners, BioNTech, Rheos Medicines, and Checkmate Pharmaceuticals, was formerly an Entrepreneur-in-Residence at Third Rock Ventures, is currently a Venture Partner for the Column Group, is a co-founder of Monimoi and Monet Lab, an equity holder in Monimoi, Juri Biosciences, Monet Lab, Clasp Therapeutics, Asher Biotherapeutics and Abata Therapeutics, and has received research funding support from Bristol-Myers Squibb. G.M.B. has sponsored research agreements through her institution with Olink Proteomics, Teiko Bio, InterVenn Biosciences, Palleon Pharmaceuticals, Astellas, and AstraZeneca. She served on advisory boards for: Iovance, Merck, Moderna, Nektar Therapeutics, Novartis, Replimune, and Ankyra Therapeutics. She consults for: Merck, InterVenn Biosciences, Iovance, and Ankyra Therapeutics. She holds stock options in Ankyra Therapeutics. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"7946"}}